Oral Astilbin Nanogels Modulate Senescence-Associated CD4⁺ T Cells and Promote T_reg Induction in Aged Mice with Colitis.

Authors

Lei Zhao, Xinyun Zhang, Qian Ren, Xue Song, Meifang Zhao, Rongshen Wang, Haocheng Du, Yan Chen, Peigen Xu, Jiangyun Liu, Jian Zhang, Jingjing Ma

Published in

Advanced science (Weinheim, Baden-Wurttemberg, Germany). Pages e78123. Oct 18, 2026. Epub Oct 18, 2026.

Abstract

Inflammatory bowel disease (IBD) in older individuals is characterized by immune senescence and deteriorating intestinal homeostasis, both of which limit the efficacy of current therapies. Here, we develop fluorinated β-glucan/pectin nanogels (F₂-Ast@NGs) for oral delivery of astilbin, a natural flavonoid with anti-inflammatory and immunoregulatory activities. This multifunctional platform integrates gastrointestinal protection, colon-targeted release, and local immune modulation. The β-glucan shell preserves nanogel stability during upper gastrointestinal transit while enabling β-glucanase-responsive disassembly in the colon. Fluorocarbon segments enhance mucus penetration, and the pectin matrix prolongs colonic retention, promoting drug accumulation at inflamed sites. In aged mice with dextran sulfate sodium (DSS)-induced colitis, F₂-Ast@NGs alleviate disease severity, attenuate senescence-associated features of colonic CD4⁺ T cells, and enhance Foxp3⁺ regulatory T cell (T_reg) responses. Concurrently, the β-glucan/pectin nanogel matrix contributes to increased short-chain fatty acid production and favorable alterations in gut microbial composition. Notably, the therapeutic efficacy of F₂-Ast@NGs is markedly attenuated in Foxp3⁺ T_reg-depleted mice, supporting an important role for T_reg-mediated immunoregulation. Collectively, F₂-Ast@NGs enable precise colonic delivery while coordinately remodeling the intestinal immune and microbial microenvironment, providing a promising oral nanotherapeutic strategy for colitis in aged hosts.

PMID:
42893426
Bibliographic data and abstract were imported from PubMed on 18 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.